贝达药业：公司定期报告按照中国证监会及深圳证券交易所的相关披露要求编制

证券之星09-24

证券之星消息，贝达药业(300558)09月24日在投资者关系平台上答复投资者关心的问题。

投资者提问：建议公司年报、半年报都聚焦于自身研发产品和拥有权益产品的研发进展，对于代销产品和别人家的产品少评判。

贝达药业回复：您好！公司定期报告按照中国证监会及深圳证券交易所的相关披露要求编制，围绕公司主营业务、产品管线及具体经营成果进行披露。公司将持续提升定期报告披露的质量，更好地向投资者介绍和展示公司产品管线。谢谢！

本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。

责任编辑：陈思雨

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2669450428?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-24 15:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2669450428","market":"fut","top_or_hot":-1,"title":"贝达药业：公司定期报告按照中国证监会及深圳证券交易所的相关披露要求编制","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/300558\">贝达药业</a>(300558)09月24日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：建议公司年报、半年报都聚焦于自身研发产品和拥有权益产品的研发进展，对于代销产品和别人家的产品少评判。</p><p>贝达药业回复：您好！公司定期报告按照中国证监会及深圳证券交易所的相关披露要求编制，围绕公司主营业务、产品管线及具体经营成果进行披露。公司将持续提升定期报告披露的质量，更好地向投资者介绍和展示公司产品管线。谢谢！</p><p>本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。</p><p>责任编辑：陈思雨</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>贝达药业：公司定期报告按照中国证监会及深圳证券交易所的相关披露要求编制</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n贝达药业：公司定期报告按照中国证监会及深圳证券交易所的相关披露要求编制\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-09-24 15:48 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026092400023473.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，贝达药业(300558)09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：建议公司年报、半年报都聚焦于自身研发产品和拥有权益产品的研发进展，对于代销产品和别人家的产品少评判。贝达药业回复：您好！公司定期报告按照中国证监会及深圳证券交易所的相关披露要求编制，围绕公司主营业务、产品管线及具体经营成果进行披露。公司将持续提升定期报告披露的质量，更好地向投资者介绍和展示公司产品...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026092400023473.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://stock.stockstar.com/RB2026092400023473.shtml","article_id":"2669450428","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2669450428","pubTimestamp":1790236111,"columns":[{"name":"A股","id":33,"label_key":"policyRegulatory"}],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，贝达药业(300558)09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：建议公司年报、半年报都聚焦于自身研发产品和拥有权益产品的研发进展，对于代销产品和别人家的产品少评判。贝达药业回复：您好！公司定期报告按照中国证监会及深圳证券交易所的相关披露要求编制，围绕公司主营业务、产品管线及具体经营成果进行披露。公司将持续提升定期报告披露的质量，更好地向投资者介绍和展示公司产品管线。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300558":"贝达药业","399001":"深证成指","BK0239":"医药制造","BK0060":"抗癌"},"translate_title":"Betta Pharma: The company's periodic reports are prepared in accordance with the relevant disclosure requirements of the China Securities Regulatory Commission and the Shenzhen Stock Exchange.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300558":1.5,"399001":1.5},"content_text":"证券之星消息，贝达药业(300558)09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：建议公司年报、半年报都聚焦于自身研发产品和拥有权益产品的研发进展，对于代销产品和别人家的产品少评判。贝达药业回复：您好！公司定期报告按照中国证监会及深圳证券交易所的相关披露要求编制，围绕公司主营业务、产品管线及具体经营成果进行披露。公司将持续提升定期报告披露的质量，更好地向投资者介绍和展示公司产品管线。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2669450428","isCrawlerRequest":true}